Patient Reported Health Related Quality of Life Outcomes After Viable Cryopreserved Umbilical Tissue Placement Directly Over Spared Neurovascular Bundles After Robotic Assisted Radical Prostatectomy

Patient Reported Health Related Quality of Life Outcomes After Viable Cryopreserved Umbilical Tissue Placement Directly Over Spared Neurovascular Bundles After Robotic Assisted Radical Prostatectomy | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Patient Reported Health Related Quality of Life Outcomes After Viable Cryopreserved Umbilical Tissue Placement Directly Over Spared Neurovascular Bundles After Robotic Assisted Radical Prostatectomy Mit Shah, Aidan Kennedy, Alexander Geisenhoff, Samantha Kraemer, and 7 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4875630/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 25 Nov, 2024 Read the published version in Journal of Robotic Surgery → Version 1 posted 8 You are reading this latest preprint version Abstract Introduction Incontinence and sexual dysfunction remain common side effects from robotic-assisted radical prostatectomy (RARP) despite nerve sparing (NS) and bladder neck reconstruction techniques. Placing growth factors and anti-inflammatory substances over neurovascular bundles is an emerging technique to enhance recovery of continence and potency. Viable cryopreserved umbilical tissue (vCUT) is FDA-approved for surgery. The objective is to determine if vCUT use in NS-RARP accelerates return of continence and sexual function. Methods A retrospective cohort of 176 patients undergoing NS-RARPs with and without vCUT from 2015-2020 was identified through the Michigan Urological Surgery Improvement Collaborative (MUSIC). Return to social urinary continence at 3, 6, and 12 months postoperatively was evaluated using MUSIC patient-reported outcomes (PRO), a validated questionnaire assessing urinary and sexual quality of life at baseline and post-treatment. A distinct cohort of 65 patients undergoing NS-RARP with and without vCUT was assessed for erections firm enough for intercourse at 12 and 24 months post-operatively using MUSIC-PRO. The association between vCUT use and social continence at 3 months was assessed via multivariable logistic regression. A descriptive analysis among patients with quality erections prior to surgery assessed the association between vCUT use and erection quality. Results Continence was achieved by 3 months post-op in 86% (99/115) of vCUT patients versus 74% (45/61) in non-vCUT patients (p=0.044). In a multivariable analysis, although not reaching conventional statistical significance, vCUT patients were more likely to achieve continence than non-vCUT patients (OR=2.21, p=0.073). At 24 months post-op, 32% of vCUT patients reported good sexual function versus 33% in non-vCUT patients (p=0.9). Conclusions vCUT use during NS-RARP is associated with quicker return to social urinary continence. However, no differences were seen in return of potency. Further studies with longer follow-up and larger sample sizes may further evaluate effectiveness of vCUT in accelerating return of postoperative continence and potency. Trial registration : N/a Radical Prostatectomy Incontinence Erectile Dysfunction Nerve Sparing Stem Cells Cryopreserved Umbilical Tissue Chorionic Membrane Patient Reported Outcomes Figures Figure 1 Figure 2 Figure 3 KEY SUMMARY POINTS The use of viable cryopreserved umbilical tissue over neurovascular bundles during nerve-sparing radical prostatectomy was associated with a higher likelihood of achieving social continence. The rate of social continence by 3 months post-op was 86% in the viable cryopreserved umbilical tissue group versus only 74% in standard nerve-sparing prostatectomy. The rate of good sexual function at 24 months post-op was 32% in the viable cryopreserved umbilical tissue group versus 33% in standard nerve-sparing prostatectomy. The use of viable cryopreserved umbilical tissue may promote a quicker return to social urinary continence after nerve-sparing prostatectomy. Further more extensive studies with longer follow up are required to further evaluate the effectiveness of this technique in accelerating the return of post-op continence and potency. INTRODUCTION Prostate cancer (PCa) is the most commonly diagnosed malignancy in men in the United States, according to the Centers for Disease Control and Prevention. 1 While new therapies in the treatment of localized prostate cancer are emerging, robotic-assisted radical prostatectomy (RARP) remains a common first-line treatment modality for localized prostate cancer. Two undesired clinical outcomes in the post-operative management of patients undergoing RARP are erectile dysfunction (ED) and urinary incontinence (UI). Potency and continence after surgery are dependent on many factors including age, pre-operative erectile function and continence, comorbidities, and surgical technique. 2 , 3 The use of the robot (da Vinci Surgical System by Intuitive Surgical) has led to enhanced surgical techniques, including nerve sparing (NS) and bladder reconstruction, that have improved functional outcomes postoperatively over the last two decades. 4 Current techniques to minimize the risk of trauma to the neurovascular bundles (NVB) include athermal dissection, minimal countertraction, and pelvic cooling, 2 , 3 , 5 , yet functional consequences remain an issue postoperatively. Even when direct injury to the NVB is avoided during surgery, it is suspected that localized post-operative inflammation leads to neuropraxia of the NVB and, consequently, a delayed return to continence and potency. 6 The use of growth factors and anti-inflammatory substances over neurovascular bundles has emerged as a technique to enhance recovery of functional outcomes. For example, the utility of viable cryopreserved placental membrane (vCPM) was demonstrated in orthopedic surgery among patients with peroneal nerve injury with previously failed surgical repair and found all patients regained motor function with resolution of foot drop after placement of vCPM over the peroneal nerve at the time of surgical re-exploration and nerve decompression. 7 Specific to the urologic setting, the use of dehydrated human amnion/chorion membrane (dHACM) placement over NVB’s at time of RARP has been studied to improve the recovery of erectile function and social continence. More recently, literature has shown that cryopreservation is a gentler preservation method for human placental membranes than dehydration. 8 Cryopreserved placental tissue retains viable cells, which has improved repair functionality in vitro and in vivo wound models. 8 Cryopreserved umbilical tissue (vCUT) composed of umbilical amnion and Wharton’s Jelly. It retains the extracellular matrix, growth factors, and endogenous neonatal mesenchymal stem cells found in placental tissue, which can provide better post-recovery parameters in comparison to standard care and potentially dHACM. vCUT provides an anti-adhesion and anti-inflammatory barrier that may also aid in wound healing. 9 vCUT is FDA -approved for use in surgery and is now being used over neurovascular bundles during prostatectomy. There is a paucity of evidence substantiating the role of cryopreserved umbilical tissue in improving functional outcomes after RARP. In this study we sought to determine if vCUT has a role in accelerating return to continence and preserving sexual function in the post-operative setting. METHODS MUSIC Michigan Urological Surgery Improvement Collaborative (MUSIC) is a quality improvement collaborative composed of multiple urologic practices across the state of Michigan and was established in 2011 with support from Blue Cross Blue Shield of Michigan. The primary goal of MUSIC is to improve the quality of care for patients with prostate cancer, kidney stones, and kidney masses in the state of Michigan. In each participating practice, trained abstractors prospectively enter standardized demographic and clinicopathologic data into an electronic registry for every newly diagnosed prostate cancer patient. Abstractors also enter data related to treatment and follow-up at fixed intervals in a patient’s course, along with validated patient-reported outcomes (PRO). Each participating MUSIC practice obtained an exemption or approval from their local institutional review board for participation in the collaborative. PRO data is collected using either the Prostate Quality of Life Survey developed and validated at Memorial Sloan Kettering Cancer Center, or the 26-item Expanded Prostate Cancer Index Composite Short Form questionnaire (EPIC-26). The EPIC-26 survey assesses urinary and sexual function on a scale from 0 to 100 points with good function for either parameter defined as a score of 74 or higher. For each survey period, an acceptable window for completion was defined as within 30 days for the three-month and six-month surveys and within 60 days for the 12-month and 24-month surveys, and surveys completed outside of the specified window were excluded from the analysis. Each participant was asked to complete a questionnaire to assess the above outcomes at baseline and at 3, 6, 12, and 24 months after surgery. Surveys were distributed via email and completed online through a web-based platform independent of the surgeons. For patients without email access, a paper version was sent via mail with a sealed return envelope to the MUSIC coordinating center. Study Design Our study was a retrospective cohort study among patients who underwent NS-RARP performed by three surgeons from 1 MUSIC practice utilizing vCUT over neurovascular bundles at the time of RARP between October 2015 and October 2020. The exposure cohort consisted of patients who received vCUT placement over their neurovascular bundles during NS-RARP; the non-exposed cohort consisted of patients who did not receive vCUT during NS-RARP. We used a standardized patient-reported outcomes survey to evaluate functional outcomes at 3, 6, 12, and 24 months after surgery to compare self-reported outcomes among patients receiving vCUT during surgery versus those that did not. Data Sources Patients of the three participating surgeons were identified through the MUSIC database. Via internal electronic medical record chart review, patients were selected and analyzed from a pool of NS-RARPs performed by surgeons also utilizing vCUT. Each participant was asked to complete the EPIC-26 questionnaire to assess their baseline functional status and bother as well as follow-up outcomes at 3, 6, 12, and 24 months after surgery. Study Population Full institutional review board (IRB) approval was granted for this study. We retrospectively reviewed data from 340 men diagnosed with localized prostate cancer who underwent NS-RARPs by surgeons utilizing vCUT at a single institution from October 2015 through October 2020. Patients were excluded if they had undergone androgen deprivation, radiation therapy, or brachytherapy before first survey response, reducing the eligible study population to 326 men. Additionally, patients were excluded from contributing to further surveys after undergoing any of these treatments post-operatively. The urinary continence study population required a baseline and 3-month survey responses for inclusion in the social urinary continence population. Baseline urinary continence was reported by 223 respondents, of which 176 also responded at 3 months. Out of the 176 patients included in the final urinary continence cohort, 115 had vCUT placed over NVBs at the time of prostatectomy, and 61 did not. Similarly, the study population for sexual function required a baseline response with good sexual function, defined as erection quality firm enough for intercourse, and a response to the erection quality question at 12 months. Among the 216 baseline respondents, 125 had good sexual function. Further, 65 also responded at 12 months. Demographics, including age, body mass index (BMI), and history of diabetes, were available for each patient. Out of the 65 patients included in the final sexual function cohort, 51 had vCUT placed at the time of prostatectomy, and 14 did not. Surgical Technique Neurovascular bundle dissection was completed bilaterally using an athermal no-touch technique. A 3x6cm piece of vCUT was saturated in 0.9% saline solution. The piece was subsequently cut into 2 even vertical strips. Next, each neurovascular bundle was sprayed with Tisseel fibrin glue (Baxter Deerfield, IL). The vCUT was placed on the medial aspect of each NVB (see Fig. 1 below). Study Variables The primary endpoints were social urinary continence (0–1 pads per day) at 3, 6, and 12 months postoperatively and erection quality firm enough for intercourse at 12 and 24 months post-operatively. Statistical Analyses Pearson’s Chi-squared test, the Wilcoxon rank sum test, and Fisher’s exact test were used to examine bivariate relationships. Multivariable logistic regression was used to assess the association between the use of vCUT and 3-month social continence adjusting for continuous variables, BMI, age, and baseline urinary incontinence score, and a categorical variable, diabetes (yes or no). Statistical analysis was done with SAS 9.4 and R version 4.3.1. P-values below 0.05 were considered statistically significant. RESULTS Patient Characteristics The urinary continence study population included a total of 176 patients between 3 surgeons (115 of these patients had vCUT utilized and 61 did not). Overall baseline continence and BMI was similar between the groups (Table 1 ). Both groups had good baseline continence (median score 100 for each) and sexual function (median score 94 for non-VCUT and 88 for VCUT group) per the EPIC-26 inventory. The vCUT group was younger than the non-vCUT group (median age 60 versus 63, p = 0.005) and had a lower prevalence of diabetes 5.2% vs 13% (p = 0.081). Continence data was available for 65% (113/174) of the original patient cohort at the final 12-month interval. The sexual function study cohort included a total of 65 patients (51 of these patients had vCUT utilized, and 14 did not). Baseline urinary continence score, baseline sexual function score, age, BMI, and history of diabetes showed no statistically significant differences between the groups. Erection quality/sexual function data was available for 50 (77%) of the cohort at the final 24 month interval. Univariate Analysis The overall rate of social continence in vCUT group vs the non-VCUT group was 86% vs 74% (p = 0.44), 94% vs 92% (p = 0.7), and 98% vs 100% (p = 0.3) at the 3, 6 and 12 month intervals, respectively (Fig. 2 ). A descriptive analysis of potency data demonstrated erections firm enough for intercourse following NS-RARP in the vCUT group vs the non-VCUT group at a rate of 28% vs 29% (p = 0.9) and 32% vs 33% (p = 0.9) at the 12- and 24-month intervals respectively (Fig. 3 ). Multivariable Analysis A multivariable analysis was performed on the 3-month continence data. Use of vCUT, baseline urinary function, BMI, age, and history of diabetes were included in the analysis. The use of vCUT did not have a statistically significant difference in odds of return to continence (OR = 2.21, 95% CI: 0.92–5.34, p = 0.073). Increase in BMI was negatively associated with return to continence (OR = 0.84, 95% CI: 0.75–0.94, p = 0.002). Age, baseline urinary function, and history of diabetes did not demonstrate statistically significant associations with return to social continence in the multivariable analysis (see Table 2 ). DISCUSSION Despite advances in surgical techniques, delays in regaining sexual function and continence continue to be problematic for patients. Neuropraxia due to post-operative inflammation could explain the delayed return to functional status. In response to this need, allograft treatment over NVBs at the time of RARP has been proposed as a technique to reduce local inflammatory cytokines and promote faster wound and nerve healing. For example, Patel et al. demonstrated that dHACM placement over NVBs at the time of NS-RARP could achieve an earlier return of continence. 6 At a 2 -month follow-up, patients treated with an allograft in this study had returned to continence at a rate of 81% compared to 74.1% in the control group. This study was underpowered and failed to demonstrate a statistical difference in overall continence rates at 2 months but did show earlier return to continence by an average of about 2 weeks among those treated with allograft in a separate analysis. Subsequently, Ogaya-Pinies et al demonstrated that dHACM placement over NVB at NS-RARP achieved earlier return to potency at all follow-up periods (1, 3, 6, and 9 months) except at 12 months. 11 This data demonstrates a quicker return of potency in the early postoperative period with placental allograft, but the analysis did not include continence data. Given the limitations of the above data and newer studies demonstrating improved placental membrane preservation with cryopreservation as opposed to dehydration 8 , we sought to study the functional outcomes with viable placental tissues (vCUT) and dehydrated membrane (dHACM). Our continence rate in the non-vCUT group (74%) appears to align with the literature demonstrating three-month social continence between 70–80% 6,12 . At the three-month follow-up, our cohort demonstrated a 12 percentage point higher rate of social continence in the vCUT group (p = 0.044). At the 6 and 12-month follow-ups, there was no statistically significant difference in rates of social continence between the vCUT and non-VCUT groups (93.6% vs 91.7%, p = 0.7 and 97.5% vs 100%, p = 0.3, respectively). Our data supports the current literature demonstrating an earlier return to social continence in groups where a placental allograft is utilized over NVBs. Though the multivariate analysis failed to achieve conventional statistical significance, the use of vCUT appeared to be associated with an increased likelihood of achieving social continence at three months, with a large effect size of a 2.21 OR. Of note, lower BMI was associated with social continence at the three-month follow-up, while age, history of diabetes, and baseline urinary continence were not significantly related to subsequent rates of continence. Given the cohort predominantly consisted of patients with good baseline continence (median EPIC 26 urinary incontinence score = 100), the role of baseline continence in the multivariable analysis was not demonstrable. We suspect this relationship would be more apparent in a cohort with more diverse pre-operative urinary function. Our potency data was limited by a small sample size, with sexual health inventory only answered by 65 patients at 12 months, 50 of which also answered at 24 months. We were able to perform a descriptive analysis of the potency data, and this demonstrated no statistically or clinically significant difference in preserving erectile function among vCUT patients at both the 12 and 24-month intervals. These results support the previous literature, which failed to demonstrate an absolute improvement in potency instead of simply an earlier return to potency. Our data was not without limitations. To provide an adequate control group for our retrospective data, our analysis was conducted on RARPs performed at a single institution and only included three surgeons. As a byproduct, we were limited by a small overall sample size. We suspect our data was underpowered to demonstrate a statistically significant association between the use of vCUT and social continence on multivariable analysis despite a large effect size for improved continence in the vCUT group. Our data was similarly underpowered in being able to conduct a multivariable analysis for potency. If we extrapolate from studies using dHACM and our preliminary results, it would be judicious to achieve a larger enrollment of patients to adequately assess the association between vCUT use and erectile function. Our data must be interpreted cautiously as we did not use age-matched cohorts for our analysis, given the limited sample size. In addition, the use of vCUT was not randomized and was up to the surgeon's discretion. This non-randomized use of vCUT could introduce bias regarding baseline patient characteristics. There was also no standardization for the situational use of vCUT among the three surgeons, and the individual demographics of each surgeon's cohort could impact the functional outcomes reported. Finally, we were unable to directly compare various formulations of allograft (i.e., viable versus dehydrated placental membrane) in vivo use during NS-RARP. Thus the subset of available literature exists in isolation and makes it difficult to extrapolate the current data to other types of allografts. Despite these limitations, this study contributes to the current literature by providing insight into the use of viable membranes as opposed to dehydrated variants and evaluating both continence and potency in a single study at a single institution. CONCLUSIONS Our data supports the notion that the use of vCUT during NS-RARP was associated with higher social continence at three months compared to those without vCUT. However, no significant difference was appreciated in regard to erectile function. This study adds to the literature supporting the study of allograft use over NVBs to improve post-operative quality of life for RARP patients. Further large-scale studies with longer follow up are required to further evaluate the effectiveness of vCUT to enhance the return of continence and potency. In addition, a head-to-head comparison of various allograft technologies in the NS-RARP setting will help guide the standard of care in the future. Declarations Funding Support for MUSIC is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and MUSIC work collaboratively, the opinions, beliefs, and viewpoints expressed by the authors do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees. Other Assistance Authorship All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Prior Presentation AUA North Central Section Meeting – Poster Presentation – Chicago, IL – October 2021 AUA National Meeting – Podium Presentation – New Orleans, LA – May 2022 Disclosures None Conflicts of Interest The authors have no conflicts of interest to disclose. References Prostate Cancer. Accessed August 6, 2021. https://www.cdc.gov/cancer/prostate/index.htm Chauhan S, Coelho RF, Rocco B, Palmer KJ, Orvieto MA, Patel VR. Techniques of nerve-sparing and potency outcomes following robot-assisted laparoscopic prostatectomy. Int Braz J Urol. 2010 May-Jun 2010;36(3):259–72. Finley DS, Osann K, Skarecky D, Ahlering TE. Hypothermic nerve-sparing radical prostatectomy: rationale, feasibility, and effect on early continence. Urology. Apr 2009;73(4):691–6. doi: 10.1016/j.urology.2008.09.085 Capogrosso P, Salonia A, Briganti A, Montorsi F. Postprostatectomy Erectile Dysfunction: A Review. World J Mens Health. Aug 2016;34(2):73–88. doi: 10.5534/wjmh.2016.34.2.73 Kowalczyk KJ, Huang AC, Hevelone ND, et al. Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol. Sep 2011;60(3):536–47. doi: 10.1016/j.eururo.2011.05.001 Patel VR, Samavedi S, Bates AS, et al. Dehydrated Human Amnion/Chorion Membrane Allograft Nerve Wrap Around the Prostatic Neurovascular Bundle Accelerates Early Return to Continence and Potency Following Robot-assisted Radical Prostatectomy: Propensity Score-matched Analysis. Eur Urol. Jun 2015;67(6):977–980. doi: 10.1016/j.eururo.2015.01.012 Rodriguez-Collazo E, Tamire Y. Open surgical implantation of a viable cryopreserved placental membrane after decompression and neurolysis of common peroneal nerve: a case series. J Orthop Surg Res. Jun 12 2017;12(1):88. doi: 10.1186/s13018-017-0587-y Johnson A, Gyurdieva A, Dhall S, Danilkovitch A, Duan-Arnold Y. Understanding the Impact of Preservation Methods on the Integrity and Functionality of Placental Allografts. Ann Plast Surg. Aug 2017;79(2):203–213. doi: 10.1097/sap.0000000000001101 Stravix Cryopreserved Placental Tissue. Accessed February 5, 2024. https://www.stravixpl.com/about Sanda MG, Wei JT, Litwin M, S. Scoring Instructions for the Expanded Prostate Cancer Index Composite Short Form (EPIC-26). University of Michigan2002. p. 1–5. Ogaya-Pinies G, Palayapalam-Ganapathi H, Rogers T, et al. Can dehydrated human amnion/chorion membrane accelerate the return to potency after a nerve-sparing robotic-assisted radical prostatectomy? Propensity score-matched analysis. J Robot Surg. Jun 2018;12(2):235–243. doi: 10.1007/s11701-017-0719-8 Holze S, Mende M, Healy KV, et al. Comparison of various continence definitions in a large group of patients undergoing radical prostatectomy: a multicentre, prospective study. BMC Urology . 2019/07/25 2019;19(1):70. doi: 10.1186/s12894-019-0500-6 Tables Table 1. Urinary continence cohort patient characteristics between the vCUT and non-vCUT groups With vCUT (N=115) Without vCUT (N=61) p Baseline Urinary Continence (out of 100) 100 (92-100) 100 (84-100) 0.11 Age (years) 60 (56-65) 63 (59-69) 0.007 BMI (kg/m 2 ) 28 (26-31) 28 (26-31) 0.6 History of Diabetes 6 (5.2%) 8 (13%) 0.081 Answered Urinary Continence Question at 6mo 94 (82%) 48 (79%) 0.6 Answered Urinary Continence Question at 12mo 79 (69%) 34 (56%) 0.088 Legend: Comparison of baseline patient characteristics between the vCUT versus standard nerve-sparing patients with vCUT. Median values for baseline continence, age, and BMI are outlined above, with IQR provided in parentheses. Diabetic history and responses to urinary continence questions at 6 and 12 months are provided as a total number in cohort and percentage of cohort in parenthesis. Table 2. Sexual Function cohort patient characteristics between the vCUT and non-vCUT groups With vCUT (N=51) Without vCUT (N=14) p Baseline Urinary Continence (out of 100) 100 (86-100) 100 (100-100) 0.2 Age (years) 60 (57-66) 66 (57-70) 0.2 BMI (kg/m 2 ) 28 (26-30) 28 (27-30) 0.9 History of Diabetes 3 (5.9%) 1 (7.1%) >0.9 Answered Sexual Function Question at 24mo 38 (75%) 12 (86%) 0.5 Legend: Comparison of baseline patient characteristics between the vCUT versus standard nerve-sparing patients with vCUT. Median values for baseline continence, age, and BMI are outlined above, with IQR provided in parentheses. Diabetic history and responses to urinary continence questions at 6 and 12 months are provided as a total number in cohort and percentage of cohort in parenthesis. Table 3. Multivariable analysis of social continence at 3 months Modulating Variables OR 95% Confidence Interval p Use of vCUT 2.21 0.92 - 5.34 0.073 Baseline Urinary Continence 1.00 0.97 - 1.03 0.8 Age 0.96 0.89 - 1.03 0.3 BMI 0.84 0.75 - 0.94 0.002 History of Diabetes 1.18 0.31 - 5.87 >0.9 Legend: Multivariable analysis of social continence (use of 0-1 pad per day) at 3 month follow-up interval controlling for other baseline patient characteristics. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 25 Nov, 2024 Read the published version in Journal of Robotic Surgery → Version 1 posted Editorial decision: Revision requested 31 Aug, 2024 Reviewers agreed at journal 29 Aug, 2024 Reviews received at journal 27 Aug, 2024 Reviewers agreed at journal 17 Aug, 2024 Reviewers invited by journal 16 Aug, 2024 Editor assigned by journal 08 Aug, 2024 Submission checks completed at journal 08 Aug, 2024 First submitted to journal 07 Aug, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4875630","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":347749505,"identity":"6ad401bd-28ac-4925-843b-1f4a4924d34b","order_by":0,"name":"Mit Shah","email":"","orcid":"","institution":"William Beaumont Hospital","correspondingAuthor":false,"prefix":"","firstName":"Mit","middleName":"","lastName":"Shah","suffix":""},{"id":347749506,"identity":"32444022-f7ca-4ca1-a2f5-342fbaaa800b","order_by":1,"name":"Aidan Kennedy","email":"data:image/png;base64,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","orcid":"","institution":"William Beaumont Hospital","correspondingAuthor":true,"prefix":"","firstName":"Aidan","middleName":"","lastName":"Kennedy","suffix":""},{"id":347749507,"identity":"949306fa-f938-4b5c-b8bb-48d84d22e955","order_by":2,"name":"Alexander Geisenhoff","email":"","orcid":"","institution":"William Beaumont Hospital","correspondingAuthor":false,"prefix":"","firstName":"Alexander","middleName":"","lastName":"Geisenhoff","suffix":""},{"id":347749508,"identity":"0cbbf143-10d1-47cc-9b00-7a0214df3f8b","order_by":3,"name":"Samantha Kraemer","email":"","orcid":"","institution":"William Beaumont Hospital","correspondingAuthor":false,"prefix":"","firstName":"Samantha","middleName":"","lastName":"Kraemer","suffix":""},{"id":347749509,"identity":"4f84db3f-429e-4bc9-98b7-6a741079f6ee","order_by":4,"name":"Chirag Dave","email":"","orcid":"","institution":"William Beaumont Hospital","correspondingAuthor":false,"prefix":"","firstName":"Chirag","middleName":"","lastName":"Dave","suffix":""},{"id":347749510,"identity":"7403bdaf-a4ea-4f4c-ad23-3eaf5f3fa2f4","order_by":5,"name":"Fiona Sun","email":"","orcid":"","institution":"William Beaumont Hospital","correspondingAuthor":false,"prefix":"","firstName":"Fiona","middleName":"","lastName":"Sun","suffix":""},{"id":347749511,"identity":"44535222-9030-4ae4-8834-148f8f3e0fd5","order_by":6,"name":"Sugandh Shetty","email":"","orcid":"","institution":"William Beaumont Hospital","correspondingAuthor":false,"prefix":"","firstName":"Sugandh","middleName":"","lastName":"Shetty","suffix":""},{"id":347749512,"identity":"a6be4076-9069-44a8-8f99-11c06489bd6d","order_by":7,"name":"Brian Seifman","email":"","orcid":"","institution":"William Beaumont Hospital","correspondingAuthor":false,"prefix":"","firstName":"Brian","middleName":"","lastName":"Seifman","suffix":""},{"id":347749513,"identity":"c727e453-ddb7-40c8-8d2f-9ed0ad29b815","order_by":8,"name":"Jason Hafron","email":"","orcid":"","institution":"William Beaumont Hospital","correspondingAuthor":false,"prefix":"","firstName":"Jason","middleName":"","lastName":"Hafron","suffix":""},{"id":347749514,"identity":"b1e56fe1-8aed-4871-bd10-94ce6dbdd3da","order_by":9,"name":"Sabir Meah","email":"","orcid":"","institution":"University of Michigan–Ann Arbor","correspondingAuthor":false,"prefix":"","firstName":"Sabir","middleName":"","lastName":"Meah","suffix":""},{"id":347749515,"identity":"8bcce584-9c50-4400-b965-3b3fa2e50919","order_by":10,"name":"Anna Johnson","email":"","orcid":"","institution":"University of Michigan–Ann Arbor","correspondingAuthor":false,"prefix":"","firstName":"Anna","middleName":"","lastName":"Johnson","suffix":""}],"badges":[],"createdAt":"2024-08-07 14:51:42","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4875630/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4875630/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s11701-024-02101-7","type":"published","date":"2024-11-25T15:56:51+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":64622732,"identity":"dd498772-2b1f-4020-936d-37480856ffae","added_by":"auto","created_at":"2024-09-16 16:52:19","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":228863,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eIntra-operative Placement of vCUT during NS-RARP\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLegend\u003c/strong\u003e: Intraoperative pictures of placement of vCUT. Figure 1A) Arrows indicate vCUT material in place overlying the neurovascular bundle. Figure 2B) Small arrow indicates right sided place vCUT material over neurovascular bundle and large arrow indicates tissue sealant being applied to left neurovascular bundle in preparation for placement of vCUT material.\u003c/p\u003e","description":"","filename":"Picture1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4875630/v1/4813425f039ff402aba06a14.jpg"},{"id":64622730,"identity":"bb75702b-9313-4c6b-bd4c-9b595086ffb6","added_by":"auto","created_at":"2024-09-16 16:52:19","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":131617,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eRate of patients socially continent over time\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLegend\u003c/strong\u003e: Line graph of rates of social continence over time with statistical comparison of rates at specified time points.\u003c/p\u003e","description":"","filename":"Picture2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4875630/v1/0c94693e89ba5f61d35c59bb.jpg"},{"id":64622731,"identity":"06dc272f-3e4b-4b81-bae3-a19c3fc7836c","added_by":"auto","created_at":"2024-09-16 16:52:19","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":112548,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eRate of patients with erections firm enough for intercourse\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLegend\u003c/strong\u003e: Post-operative sexual function rates at 12 and 24 months separated by patient who received vCUT versus standard nerve sparing without vCUT.\u003c/p\u003e","description":"","filename":"Picture3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-4875630/v1/5f019fbbf000c895c468f037.jpg"},{"id":70382831,"identity":"3d628056-4433-46bd-a85e-557239e5f0a4","added_by":"auto","created_at":"2024-12-02 16:32:39","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1131998,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4875630/v1/ed8711d1-11ae-4305-b25e-31e30f90850e.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Patient Reported Health Related Quality of Life Outcomes After Viable Cryopreserved Umbilical Tissue Placement Directly Over Spared Neurovascular Bundles After Robotic Assisted Radical Prostatectomy","fulltext":[{"header":"KEY SUMMARY POINTS ","content":"\u003cul\u003e\n \u003cli\u003eThe use of viable cryopreserved umbilical tissue over neurovascular bundles during nerve-sparing radical prostatectomy was associated with a higher likelihood of achieving social continence.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eThe rate of social continence by 3 months post-op was 86% in the viable cryopreserved umbilical tissue group versus only 74% in standard nerve-sparing prostatectomy.\u003c/li\u003e\n \u003cli\u003eThe rate of good sexual function at 24 months post-op was 32%\u0026nbsp;in the viable cryopreserved umbilical tissue group versus 33% in standard nerve-sparing prostatectomy.\u003c/li\u003e\n \u003cli\u003eThe use of viable cryopreserved umbilical tissue may promote a quicker return to social urinary continence after nerve-sparing prostatectomy.\u003c/li\u003e\n \u003cli\u003eFurther more extensive studies with longer follow up are required to further evaluate the effectiveness of this technique in accelerating the return of post-op continence and potency.\u003c/li\u003e\n\u003c/ul\u003e"},{"header":"INTRODUCTION","content":"\u003cp\u003eProstate cancer (PCa) is the most commonly diagnosed malignancy in men in the United States, according to the Centers for Disease Control and Prevention.\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e While new therapies in the treatment of localized prostate cancer are emerging, robotic-assisted radical prostatectomy (RARP) remains a common first-line treatment modality for localized prostate cancer. Two undesired clinical outcomes in the post-operative management of patients undergoing RARP are erectile dysfunction (ED) and urinary incontinence (UI).\u003c/p\u003e \u003cp\u003ePotency and continence after surgery are dependent on many factors including age, pre-operative erectile function and continence, comorbidities, and surgical technique.\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e The use of the robot (da Vinci Surgical System by Intuitive Surgical) has led to enhanced surgical techniques, including nerve sparing (NS) and bladder reconstruction, that have improved functional outcomes postoperatively over the last two decades.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e Current techniques to minimize the risk of trauma to the neurovascular bundles (NVB) include athermal dissection, minimal countertraction, and pelvic cooling,\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e,\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e, yet functional consequences remain an issue postoperatively. Even when direct injury to the NVB is avoided during surgery, it is suspected that localized post-operative inflammation leads to neuropraxia of the NVB and, consequently, a delayed return to continence and potency.\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eThe use of growth factors and anti-inflammatory substances over neurovascular bundles has emerged as a technique to enhance recovery of functional outcomes. For example, the utility of viable cryopreserved placental membrane (vCPM) was demonstrated in orthopedic surgery among patients with peroneal nerve injury with previously failed surgical repair and found all patients regained motor function with resolution of foot drop after placement of vCPM over the peroneal nerve at the time of surgical re-exploration and nerve decompression.\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e Specific to the urologic setting, the use of dehydrated human amnion/chorion membrane (dHACM) placement over NVB\u0026rsquo;s at time of RARP has been studied to improve the recovery of erectile function and social continence. More recently, literature has shown that cryopreservation is a gentler preservation method for human placental membranes than dehydration.\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e Cryopreserved placental tissue retains viable cells, which has improved repair functionality in vitro and in vivo wound models.\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eCryopreserved umbilical tissue (vCUT) composed of umbilical amnion and Wharton\u0026rsquo;s Jelly. It retains the extracellular matrix, growth factors, and endogenous neonatal mesenchymal stem cells found in placental tissue, which can provide better post-recovery parameters in comparison to standard care and potentially dHACM. vCUT provides an anti-adhesion and anti-inflammatory barrier that may also aid in wound healing. \u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003evCUT is FDA -approved for use in surgery and is now being used over neurovascular bundles during prostatectomy. There is a paucity of evidence substantiating the role of cryopreserved umbilical tissue in improving functional outcomes after RARP. In this study we sought to determine if vCUT has a role in accelerating return to continence and preserving sexual function in the post-operative setting.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eMUSIC\u003c/h2\u003e \u003cp\u003eMichigan Urological Surgery Improvement Collaborative (MUSIC) is a quality improvement collaborative composed of multiple urologic practices across the state of Michigan and was established in 2011 with support from Blue Cross Blue Shield of Michigan. The primary goal of MUSIC is to improve the quality of care for patients with prostate cancer, kidney stones, and kidney masses in the state of Michigan. In each participating practice, trained abstractors prospectively enter standardized demographic and clinicopathologic data into an electronic registry for every newly diagnosed prostate cancer patient. Abstractors also enter data related to treatment and follow-up at fixed intervals in a patient\u0026rsquo;s course, along with validated patient-reported outcomes (PRO). Each participating MUSIC practice obtained an exemption or approval from their local institutional review board for participation in the collaborative. PRO data is collected using either the Prostate Quality of Life Survey developed and validated at Memorial Sloan Kettering Cancer Center, or the 26-item Expanded Prostate Cancer Index Composite Short Form questionnaire (EPIC-26). The EPIC-26 survey assesses urinary and sexual function on a scale from 0 to 100 points with good function for either parameter defined as a score of 74 or higher. For each survey period, an acceptable window for completion was defined as within 30 days for the three-month and six-month surveys and within 60 days for the 12-month and 24-month surveys, and surveys completed outside of the specified window were excluded from the analysis. Each participant was asked to complete a questionnaire to assess the above outcomes at baseline and at 3, 6, 12, and 24 months after surgery. Surveys were distributed via email and completed online through a web-based platform independent of the surgeons. For patients without email access, a paper version was sent via mail with a sealed return envelope to the MUSIC coordinating center.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eStudy Design\u003c/h2\u003e \u003cp\u003eOur study was a retrospective cohort study among patients who underwent NS-RARP performed by three surgeons from 1 MUSIC practice utilizing vCUT over neurovascular bundles at the time of RARP between October 2015 and October 2020. The exposure cohort consisted of patients who received vCUT placement over their neurovascular bundles during NS-RARP; the non-exposed cohort consisted of patients who did not receive vCUT during NS-RARP. We used a standardized patient-reported outcomes survey to evaluate functional outcomes at 3, 6, 12, and 24 months after surgery to compare self-reported outcomes among patients receiving vCUT during surgery versus those that did not.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eData Sources\u003c/h2\u003e \u003cp\u003ePatients of the three participating surgeons were identified through the MUSIC database. Via internal electronic medical record chart review, patients were selected and analyzed from a pool of NS-RARPs performed by surgeons also utilizing vCUT. Each participant was asked to complete the EPIC-26 questionnaire to assess their baseline functional status and bother as well as follow-up outcomes at 3, 6, 12, and 24 months after surgery.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eStudy Population\u003c/h2\u003e \u003cp\u003eFull institutional review board (IRB) approval was granted for this study. We retrospectively reviewed data from 340 men diagnosed with localized prostate cancer who underwent NS-RARPs by surgeons utilizing vCUT at a single institution from October 2015 through October 2020. Patients were excluded if they had undergone androgen deprivation, radiation therapy, or brachytherapy before first survey response, reducing the eligible study population to 326 men. Additionally, patients were excluded from contributing to further surveys after undergoing any of these treatments post-operatively. The urinary continence study population required a baseline and 3-month survey responses for inclusion in the social urinary continence population. Baseline urinary continence was reported by 223 respondents, of which 176 also responded at 3 months. Out of the 176 patients included in the final urinary continence cohort, 115 had vCUT placed over NVBs at the time of prostatectomy, and 61 did not.\u003c/p\u003e \u003cp\u003eSimilarly, the study population for sexual function required a baseline response with good sexual function, defined as erection quality firm enough for intercourse, and a response to the erection quality question at 12 months. Among the 216 baseline respondents, 125 had good sexual function. Further, 65 also responded at 12 months. Demographics, including age, body mass index (BMI), and history of diabetes, were available for each patient. Out of the 65 patients included in the final sexual function cohort, 51 had vCUT placed at the time of prostatectomy, and 14 did not.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eSurgical Technique\u003c/h2\u003e \u003cp\u003eNeurovascular bundle dissection was completed bilaterally using an athermal no-touch technique. A 3x6cm piece of vCUT was saturated in 0.9% saline solution. The piece was subsequently cut into 2 even vertical strips. Next, each neurovascular bundle was sprayed with Tisseel fibrin glue (Baxter Deerfield, IL). The vCUT was placed on the medial aspect of each NVB (see Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e below).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eStudy Variables\u003c/h2\u003e \u003cp\u003eThe primary endpoints were social urinary continence (0\u0026ndash;1 pads per day) at 3, 6, and 12 months postoperatively and erection quality firm enough for intercourse at 12 and 24 months post-operatively.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eStatistical Analyses\u003c/h2\u003e \u003cp\u003ePearson\u0026rsquo;s Chi-squared test, the Wilcoxon rank sum test, and Fisher\u0026rsquo;s exact test were used to examine bivariate relationships. Multivariable logistic regression was used to assess the association between the use of vCUT and 3-month social continence adjusting for continuous variables, BMI, age, and baseline urinary incontinence score, and a categorical variable, diabetes (yes or no). Statistical analysis was done with SAS 9.4 and R version 4.3.1. P-values below 0.05 were considered statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec11\"\u003e\n \u003ch2\u003ePatient Characteristics\u003c/h2\u003e\n \u003cp\u003eThe urinary continence study population included a total of 176 patients between 3 surgeons (115 of these patients had vCUT utilized and 61 did not). Overall baseline continence and BMI was similar between the groups (Table \u003cspan\u003e1\u003c/span\u003e). Both groups had good baseline continence (median score 100 for each) and sexual function (median score 94 for non-VCUT and 88 for VCUT group) per the EPIC-26 inventory. The vCUT group was younger than the non-vCUT group (median age 60 versus 63, p\u0026thinsp;=\u0026thinsp;0.005) and had a lower prevalence of diabetes 5.2% vs 13% (p\u0026thinsp;=\u0026thinsp;0.081). Continence data was available for 65% (113/174) of the original patient cohort at the final 12-month interval.\u003c/p\u003e\n \u003cp\u003eThe sexual function study cohort included a total of 65 patients (51 of these patients had vCUT utilized, and 14 did not). Baseline urinary continence score, baseline sexual function score, age, BMI, and history of diabetes showed no statistically significant differences between the groups. Erection quality/sexual function data was available for 50 (77%) of the cohort at the final 24 month interval.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec12\"\u003e\n \u003ch2\u003eUnivariate Analysis\u003c/h2\u003e\n \u003cp\u003eThe overall rate of social continence in vCUT group vs the non-VCUT group was 86% vs 74% (p\u0026thinsp;=\u0026thinsp;0.44), 94% vs 92% (p\u0026thinsp;=\u0026thinsp;0.7), and 98% vs 100% (p\u0026thinsp;=\u0026thinsp;0.3) at the 3, 6 and 12 month intervals, respectively (Fig. \u003cspan\u003e2\u003c/span\u003e). A descriptive analysis of potency data demonstrated erections firm enough for intercourse following NS-RARP in the vCUT group vs the non-VCUT group at a rate of 28% vs 29% (p\u0026thinsp;=\u0026thinsp;0.9) and 32% vs 33% (p\u0026thinsp;=\u0026thinsp;0.9) at the 12- and 24-month intervals respectively (Fig. \u003cspan\u003e3\u003c/span\u003e).\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec13\"\u003e\n \u003ch2\u003eMultivariable Analysis\u003c/h2\u003e\n \u003cp\u003eA multivariable analysis was performed on the 3-month continence data. Use of vCUT, baseline urinary function, BMI, age, and history of diabetes were included in the analysis. The use of vCUT did not have a statistically significant difference in odds of return to continence (OR\u0026thinsp;=\u0026thinsp;2.21, 95% CI: 0.92\u0026ndash;5.34, p\u0026thinsp;=\u0026thinsp;0.073). Increase in BMI was negatively associated with return to continence (OR\u0026thinsp;=\u0026thinsp;0.84, 95% CI: 0.75\u0026ndash;0.94, p\u0026thinsp;=\u0026thinsp;0.002). Age, baseline urinary function, and history of diabetes did not demonstrate statistically significant associations with return to social continence in the multivariable analysis (see Table \u003cspan\u003e2\u003c/span\u003e).\u003c/p\u003e\n\u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eDespite advances in surgical techniques, delays in regaining sexual function and continence continue to be problematic for patients. Neuropraxia due to post-operative inflammation could explain the delayed return to functional status. In response to this need, allograft treatment over NVBs at the time of RARP has been proposed as a technique to reduce local inflammatory cytokines and promote faster wound and nerve healing.\u003c/p\u003e \u003cp\u003eFor example, Patel et al. demonstrated that dHACM placement over NVBs at the time of NS-RARP could achieve an earlier return of continence.\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e At a 2 -month follow-up, patients treated with an allograft in this study had returned to continence at a rate of 81% compared to 74.1% in the control group. This study was underpowered and failed to demonstrate a statistical difference in overall continence rates at 2 months but did show earlier return to continence by an average of about 2 weeks among those treated with allograft in a separate analysis. Subsequently, Ogaya-Pinies et al demonstrated that dHACM placement over NVB at NS-RARP achieved earlier return to potency at all follow-up periods (1, 3, 6, and 9 months) except at 12 months.\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e This data demonstrates a quicker return of potency in the early postoperative period with placental allograft, but the analysis did not include continence data. Given the limitations of the above data and newer studies demonstrating improved placental membrane preservation with cryopreservation as opposed to dehydration\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e, we sought to study the functional outcomes with viable placental tissues (vCUT) and dehydrated membrane (dHACM).\u003c/p\u003e \u003cp\u003eOur continence rate in the non-vCUT group (74%) appears to align with the literature demonstrating three-month social continence between 70\u0026ndash;80%\u003csup\u003e6,12\u003c/sup\u003e. At the three-month follow-up, our cohort demonstrated a 12 percentage point higher rate of social continence in the vCUT group (p\u0026thinsp;=\u0026thinsp;0.044). At the 6 and 12-month follow-ups, there was no statistically significant difference in rates of social continence between the vCUT and non-VCUT groups (93.6% vs 91.7%, p\u0026thinsp;=\u0026thinsp;0.7 and 97.5% vs 100%, p\u0026thinsp;=\u0026thinsp;0.3, respectively). Our data supports the current literature demonstrating an earlier return to social continence in groups where a placental allograft is utilized over NVBs. Though the multivariate analysis failed to achieve conventional statistical significance, the use of vCUT appeared to be associated with an increased likelihood of achieving social continence at three months, with a large effect size of a 2.21 OR. Of note, lower BMI was associated with social continence at the three-month follow-up, while age, history of diabetes, and baseline urinary continence were not significantly related to subsequent rates of continence. Given the cohort predominantly consisted of patients with good baseline continence (median EPIC 26 urinary incontinence score\u0026thinsp;=\u0026thinsp;100), the role of baseline continence in the multivariable analysis was not demonstrable. We suspect this relationship would be more apparent in a cohort with more diverse pre-operative urinary function.\u003c/p\u003e \u003cp\u003eOur potency data was limited by a small sample size, with sexual health inventory only answered by 65 patients at 12 months, 50 of which also answered at 24 months. We were able to perform a descriptive analysis of the potency data, and this demonstrated no statistically or clinically significant difference in preserving erectile function among vCUT patients at both the 12 and 24-month intervals. These results support the previous literature, which failed to demonstrate an absolute improvement in potency instead of simply an earlier return to potency.\u003c/p\u003e \u003cp\u003eOur data was not without limitations. To provide an adequate control group for our retrospective data, our analysis was conducted on RARPs performed at a single institution and only included three surgeons. As a byproduct, we were limited by a small overall sample size. We suspect our data was underpowered to demonstrate a statistically significant association between the use of vCUT and social continence on multivariable analysis despite a large effect size for improved continence in the vCUT group. Our data was similarly underpowered in being able to conduct a multivariable analysis for potency. If we extrapolate from studies using dHACM and our preliminary results, it would be judicious to achieve a larger enrollment of patients to adequately assess the association between vCUT use and erectile function. Our data must be interpreted cautiously as we did not use age-matched cohorts for our analysis, given the limited sample size. In addition, the use of vCUT was not randomized and was up to the surgeon's discretion. This non-randomized use of vCUT could introduce bias regarding baseline patient characteristics. There was also no standardization for the situational use of vCUT among the three surgeons, and the individual demographics of each surgeon's cohort could impact the functional outcomes reported. Finally, we were unable to directly compare various formulations of allograft (i.e., viable versus dehydrated placental membrane) in vivo use during NS-RARP. Thus the subset of available literature exists in isolation and makes it difficult to extrapolate the current data to other types of allografts. Despite these limitations, this study contributes to the current literature by providing insight into the use of viable membranes as opposed to dehydrated variants and evaluating both continence and potency in a single study at a single institution.\u003c/p\u003e"},{"header":"CONCLUSIONS","content":"\u003cp\u003eOur data supports the notion that the use of vCUT during NS-RARP was associated with higher social continence at three months compared to those without vCUT. However, no significant difference was appreciated in regard to erectile function. This study adds to the literature supporting the study of allograft use over NVBs to improve post-operative quality of life for RARP patients. Further large-scale studies with longer follow up are required to further evaluate the effectiveness of vCUT to enhance the return of continence and potency. In addition, a head-to-head comparison of various allograft technologies in the NS-RARP setting will help guide the standard of care in the future.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003e\u003cem\u003eFunding\u003c/em\u003e\u003c/h2\u003e\n\u003cp\u003eSupport for MUSIC is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program. \u0026nbsp; Although Blue Cross Blue Shield of Michigan and MUSIC work collaboratively, the opinions, beliefs, and viewpoints expressed by the authors do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.\u003c/p\u003e\n\u003ch2\u003e\u003cem\u003eOther Assistance\u003c/em\u003e\u003c/h2\u003e\n\u003ch2\u003e\u003cem\u003eAuthorship\u003c/em\u003e\u003c/h2\u003e\n\u003cp\u003eAll named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.\u003c/p\u003e\n\u003ch2\u003e\u003cem\u003ePrior Presentation\u003c/em\u003e\u003c/h2\u003e\n\u003cp\u003eAUA North Central Section Meeting \u0026ndash; Poster Presentation \u0026ndash; Chicago, IL \u0026ndash; October 2021\u003c/p\u003e\n\u003cp\u003eAUA National Meeting \u0026ndash; Podium Presentation \u0026ndash; New Orleans, LA \u0026ndash; May 2022\u003c/p\u003e\n\u003ch2\u003e\u003cem\u003eDisclosures\u003c/em\u003e\u003c/h2\u003e\n\u003cp\u003eNone\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eConflicts of Interest\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors have no conflicts of interest to disclose.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eProstate Cancer. Accessed August 6, 2021. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.cdc.gov/cancer/prostate/index.htm\u003c/span\u003e\u003cspan address=\"https://www.cdc.gov/cancer/prostate/index.htm\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChauhan S, Coelho RF, Rocco B, Palmer KJ, Orvieto MA, Patel VR. Techniques of nerve-sparing and potency outcomes following robot-assisted laparoscopic prostatectomy. Int Braz J Urol. 2010 May-Jun 2010;36(3):259\u0026ndash;72.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFinley DS, Osann K, Skarecky D, Ahlering TE. Hypothermic nerve-sparing radical prostatectomy: rationale, feasibility, and effect on early continence. Urology. Apr 2009;73(4):691\u0026ndash;6. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.urology.2008.09.085\u003c/span\u003e\u003cspan address=\"10.1016/j.urology.2008.09.085\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCapogrosso P, Salonia A, Briganti A, Montorsi F. Postprostatectomy Erectile Dysfunction: A Review. World J Mens Health. Aug 2016;34(2):73\u0026ndash;88. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.5534/wjmh.2016.34.2.73\u003c/span\u003e\u003cspan address=\"10.5534/wjmh.2016.34.2.73\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKowalczyk KJ, Huang AC, Hevelone ND, et al. Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol. Sep 2011;60(3):536\u0026ndash;47. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2011.05.001\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2011.05.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePatel VR, Samavedi S, Bates AS, et al. Dehydrated Human Amnion/Chorion Membrane Allograft Nerve Wrap Around the Prostatic Neurovascular Bundle Accelerates Early Return to Continence and Potency Following Robot-assisted Radical Prostatectomy: Propensity Score-matched Analysis. Eur Urol. Jun 2015;67(6):977\u0026ndash;980. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.eururo.2015.01.012\u003c/span\u003e\u003cspan address=\"10.1016/j.eururo.2015.01.012\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRodriguez-Collazo E, Tamire Y. Open surgical implantation of a viable cryopreserved placental membrane after decompression and neurolysis of common peroneal nerve: a case series. J Orthop Surg Res. Jun 12 2017;12(1):88. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s13018-017-0587-y\u003c/span\u003e\u003cspan address=\"10.1186/s13018-017-0587-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJohnson A, Gyurdieva A, Dhall S, Danilkovitch A, Duan-Arnold Y. Understanding the Impact of Preservation Methods on the Integrity and Functionality of Placental Allografts. Ann Plast Surg. Aug 2017;79(2):203\u0026ndash;213. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/sap.0000000000001101\u003c/span\u003e\u003cspan address=\"10.1097/sap.0000000000001101\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStravix Cryopreserved Placental Tissue. Accessed February 5, 2024. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.stravixpl.com/about\u003c/span\u003e\u003cspan address=\"https://www.stravixpl.com/about\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSanda MG, Wei JT, Litwin M, S. Scoring Instructions for the Expanded Prostate Cancer Index Composite Short Form (EPIC-26). University of Michigan2002. p. 1\u0026ndash;5.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOgaya-Pinies G, Palayapalam-Ganapathi H, Rogers T, et al. Can dehydrated human amnion/chorion membrane accelerate the return to potency after a nerve-sparing robotic-assisted radical prostatectomy? Propensity score-matched analysis. J Robot Surg. Jun 2018;12(2):235\u0026ndash;243. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s11701-017-0719-8\u003c/span\u003e\u003cspan address=\"10.1007/s11701-017-0719-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHolze S, Mende M, Healy KV, et al. Comparison of various continence definitions in a large group of patients undergoing radical prostatectomy: a multicentre, prospective study. \u003cem\u003eBMC Urology\u003c/em\u003e. 2019/07/25 2019;19(1):70. doi:\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s12894-019-0500-6\u003c/span\u003e\u003cspan address=\"10.1186/s12894-019-0500-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"631\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"4\" valign=\"bottom\" style=\"width: 75.0803%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTable 1. Urinary continence cohort patient characteristics between the vCUT and non-vCUT groups\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" valign=\"bottom\" style=\"width: 21.331%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 21.4515%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eWith\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;vCUT\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(N=115)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 22.2951%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eWithout\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;vCUT\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(N=61)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.8822%;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 21.331%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBaseline Urinary Continence (out of 100)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 21.4515%;\"\u003e\n \u003cp\u003e100 (92-100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 22.2951%;\"\u003e\n \u003cp\u003e100 (84-100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.8822%;\"\u003e\n \u003cp\u003e0.11\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 21.331%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (years)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 21.4515%;\"\u003e\n \u003cp\u003e60 (56-65)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 22.2951%;\"\u003e\n \u003cp\u003e63 (59-69)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.8822%;\"\u003e\n \u003cp\u003e0.007\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 21.331%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBMI (kg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 21.4515%;\"\u003e\n \u003cp\u003e28 (26-31)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 22.2951%;\"\u003e\n \u003cp\u003e28 (26-31)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.8822%;\"\u003e\n \u003cp\u003e0.6\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 21.331%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHistory of Diabetes\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 21.4515%;\"\u003e\n \u003cp\u003e6 (5.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 22.2951%;\"\u003e\n \u003cp\u003e8 (13%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.8822%;\"\u003e\n \u003cp\u003e0.081\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 21.331%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAnswered Urinary Continence Question at 6mo\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 21.4515%;\"\u003e\n \u003cp\u003e94 (82%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 22.2951%;\"\u003e\n \u003cp\u003e48 (79%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.8822%;\"\u003e\n \u003cp\u003e0.6\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 21.331%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAnswered Urinary Continence Question at 12mo\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 21.4515%;\"\u003e\n \u003cp\u003e79 (69%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 22.2951%;\"\u003e\n \u003cp\u003e34 (56%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.8822%;\"\u003e\n \u003cp\u003e0.088\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eLegend:\u0026nbsp;\u003c/strong\u003eComparison of baseline patient characteristics between the vCUT versus standard nerve-sparing patients with vCUT. Median values for baseline continence, age, and BMI are outlined above, with IQR provided in parentheses. Diabetic history and responses to urinary continence questions at 6 and 12 months are provided as a total number in cohort and percentage of cohort in parenthesis.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"631\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"100%\" colspan=\"4\" valign=\"bottom\" style=\"width: 72.6531%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003eTable 2. Sexual Function cohort patient characteristics between the vCUT and non-vCUT groups\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" valign=\"bottom\" style=\"width: 20.6414%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 20.758%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eWith\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;vCUT\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(N=51)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 21.5743%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eWithout\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;vCUT\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e(N=14)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.7959%;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 20.6414%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBaseline Urinary Continence (out of 100)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 20.758%;\"\u003e\n \u003cp\u003e100 (86-100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 21.5743%;\"\u003e\n \u003cp\u003e100 (100-100)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.7959%;\"\u003e\n \u003cp\u003e0.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 20.6414%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge (years)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 20.758%;\"\u003e\n \u003cp\u003e60 (57-66)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 21.5743%;\"\u003e\n \u003cp\u003e66 (57-70)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.7959%;\"\u003e\n \u003cp\u003e0.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 20.6414%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBMI (kg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 20.758%;\"\u003e\n \u003cp\u003e28 (26-30)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 21.5743%;\"\u003e\n \u003cp\u003e28 (27-30)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.7959%;\"\u003e\n \u003cp\u003e0.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 20.6414%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHistory of Diabetes\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 20.758%;\"\u003e\n \u003cp\u003e3 (5.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 21.5743%;\"\u003e\n \u003cp\u003e1 (7.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.7959%;\"\u003e\n \u003cp\u003e\u0026gt;0.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"28.32278481012658%\" style=\"width: 20.6414%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAnswered Sexual Function Question at 24mo\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.481012658227847%\" style=\"width: 20.758%;\"\u003e\n \u003cp\u003e38 (75%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.588607594936708%\" style=\"width: 21.5743%;\"\u003e\n \u003cp\u003e12 (86%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.60759493670886%\" style=\"width: 9.7959%;\"\u003e\n \u003cp\u003e0.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eLegend:\u0026nbsp;\u003c/strong\u003eComparison of baseline patient characteristics between the vCUT versus standard nerve-sparing patients with vCUT. Median values for baseline continence, age, and BMI are outlined above, with IQR provided in parentheses. Diabetic history and responses to urinary continence questions at 6 and 12 months are provided as a total number in cohort and percentage of cohort in parenthesis.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"539\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"97.21706864564007%\" colspan=\"4\" valign=\"bottom\" style=\"width: 72.7273%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTable 3. Multivariable analysis of social continence at 3 months\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"39.03345724907063%\" style=\"width: 25.7576%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eModulating Variables\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.895910780669144%\" style=\"width: 7.8512%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eOR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"35.13011152416357%\" style=\"width: 31.8182%;\"\u003e\n \u003cp\u003e\u003cstrong\u003e95% Confidence Interval\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.152416356877323%\" style=\"width: 7.3003%;\"\u003e\n \u003cp\u003e\u003cstrong\u003ep\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"39.03345724907063%\" valign=\"top\" style=\"width: 25.7576%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eUse of vCUT\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.895910780669144%\" style=\"width: 7.8512%;\"\u003e\n \u003cp\u003e2.21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"35.13011152416357%\" style=\"width: 31.8182%;\"\u003e\n \u003cp\u003e0.92 - 5.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.152416356877323%\" style=\"width: 7.3003%;\"\u003e\n \u003cp\u003e0.073\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"39.03345724907063%\" valign=\"top\" style=\"width: 25.7576%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBaseline Urinary Continence\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.895910780669144%\" style=\"width: 7.8512%;\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"35.13011152416357%\" style=\"width: 31.8182%;\"\u003e\n \u003cp\u003e0.97 - 1.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.152416356877323%\" style=\"width: 7.3003%;\"\u003e\n \u003cp\u003e0.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"39.03345724907063%\" valign=\"top\" style=\"width: 25.7576%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAge\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.895910780669144%\" style=\"width: 7.8512%;\"\u003e\n \u003cp\u003e0.96\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"35.13011152416357%\" style=\"width: 31.8182%;\"\u003e\n \u003cp\u003e0.89 - 1.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.152416356877323%\" style=\"width: 7.3003%;\"\u003e\n \u003cp\u003e0.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"39.03345724907063%\" valign=\"top\" style=\"width: 25.7576%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eBMI\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.895910780669144%\" style=\"width: 7.8512%;\"\u003e\n \u003cp\u003e0.84\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"35.13011152416357%\" style=\"width: 31.8182%;\"\u003e\n \u003cp\u003e0.75 - 0.94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.152416356877323%\" style=\"width: 7.3003%;\"\u003e\n \u003cp\u003e0.002\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"39.03345724907063%\" valign=\"top\" style=\"width: 25.7576%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eHistory of Diabetes\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.895910780669144%\" style=\"width: 7.8512%;\"\u003e\n \u003cp\u003e1.18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"35.13011152416357%\" style=\"width: 31.8182%;\"\u003e\n \u003cp\u003e0.31 - 5.87\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"11.152416356877323%\" style=\"width: 7.3003%;\"\u003e\n \u003cp\u003e\u0026gt;0.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eLegend:\u0026nbsp;\u003c/strong\u003eMultivariable analysis of social continence (use of 0-1 pad per day) at 3 month follow-up interval controlling for other baseline patient characteristics.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"journal-of-robotic-surgery","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jors","sideBox":"Learn more about [Journal of Robotic Surgery](http://link.springer.com/journal/11701)","snPcode":"11701","submissionUrl":"https://submission.nature.com/new-submission/11701/3","title":"Journal of Robotic Surgery","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Radical Prostatectomy, Incontinence, Erectile Dysfunction, Nerve Sparing, Stem Cells, Cryopreserved Umbilical Tissue, Chorionic Membrane, Patient Reported Outcomes","lastPublishedDoi":"10.21203/rs.3.rs-4875630/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4875630/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eIntroduction\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIncontinence and sexual dysfunction remain common side effects from robotic-assisted radical prostatectomy (RARP) despite nerve sparing (NS) and bladder neck reconstruction techniques. Placing growth factors and anti-inflammatory substances over neurovascular bundles is an emerging technique to enhance recovery of continence and potency. Viable cryopreserved umbilical tissue (vCUT) is FDA-approved for surgery. The objective is to determine if vCUT use in NS-RARP accelerates return of continence and sexual function.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA retrospective cohort of 176 patients undergoing NS-RARPs with and without vCUT from 2015-2020 was identified through the Michigan Urological Surgery Improvement Collaborative (MUSIC). Return to social urinary continence at 3, 6, and 12 months postoperatively was evaluated using MUSIC patient-reported outcomes (PRO), a validated questionnaire assessing urinary and sexual quality of life at baseline and post-treatment. A distinct cohort of 65 patients undergoing NS-RARP with and without vCUT was assessed for erections firm enough for intercourse at 12 and 24 months post-operatively using MUSIC-PRO. \u0026nbsp;The association between vCUT use and social continence at 3 months was assessed via multivariable logistic regression. A descriptive analysis among patients with quality erections prior to surgery assessed the association between vCUT use and erection quality.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eContinence was achieved by 3 months post-op in 86% (99/115) of vCUT patients versus 74% (45/61) in non-vCUT patients (p=0.044). In a multivariable analysis, although not reaching conventional statistical significance, vCUT patients were more likely to achieve continence than non-vCUT patients (OR=2.21, p=0.073). At 24 months post-op, 32% of vCUT patients reported good sexual function versus 33% in non-vCUT patients (p=0.9).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003evCUT use during NS-RARP is associated with quicker return to social urinary continence. However, no differences were seen in return of potency. Further studies with longer follow-up and larger sample sizes may further evaluate effectiveness of vCUT in accelerating return of postoperative continence and potency.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTrial registration\u003c/strong\u003e: N/a\u003c/p\u003e","manuscriptTitle":"Patient Reported Health Related Quality of Life Outcomes After Viable Cryopreserved Umbilical Tissue Placement Directly Over Spared Neurovascular Bundles After Robotic Assisted Radical Prostatectomy","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-09-16 16:52:15","doi":"10.21203/rs.3.rs-4875630/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-08-31T16:02:20+00:00","index":"","fulltext":""},{"type":"reviewerAgreed","content":"290100358751060928637675676570095444139","date":"2024-08-29T12:07:46+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-08-27T21:51:31+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"306378472997381758658623357509673983907","date":"2024-08-17T09:04:46+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-08-16T19:44:58+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-08-09T00:15:48+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-08-08T12:05:39+00:00","index":"","fulltext":""},{"type":"submitted","content":"Journal of Robotic Surgery","date":"2024-08-07T14:50:16+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"journal-of-robotic-surgery","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jors","sideBox":"Learn more about [Journal of Robotic Surgery](http://link.springer.com/journal/11701)","snPcode":"11701","submissionUrl":"https://submission.nature.com/new-submission/11701/3","title":"Journal of Robotic Surgery","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"28f571d5-d1a4-41bc-9ee6-2a9db95535f3","owner":[],"postedDate":"September 16th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-12-02T16:04:23+00:00","versionOfRecord":{"articleIdentity":"rs-4875630","link":"https://doi.org/10.1007/s11701-024-02101-7","journal":{"identity":"journal-of-robotic-surgery","isVorOnly":false,"title":"Journal of Robotic Surgery"},"publishedOn":"2024-11-25 15:56:51","publishedOnDateReadable":"November 25th, 2024"},"versionCreatedAt":"2024-09-16 16:52:15","video":"","vorDoi":"10.1007/s11701-024-02101-7","vorDoiUrl":"https://doi.org/10.1007/s11701-024-02101-7","workflowStages":[]},"version":"v1","identity":"rs-4875630","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4875630","identity":"rs-4875630","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}